mutations, in whom rituximab appears to acquire very little included benefit.59 Other genomic subgroups, such as sufferers with BIRC3mutations given The truth that, as explained below, CLL therapy is predicated to the existence or absence of such mutations. The existing consensus is the fact, in addition to clonal mutations, subclonal mutations tha